Does CellCept (Mycophenolate Mofetil) Cause Leukocytosis?
No, CellCept does not cause leukocytosis (elevated white blood cell count); instead, it commonly causes leukopenia (low white blood cell count) as one of its principal hematologic adverse effects. 1, 2
Hematologic Effects of Mycophenolate Mofetil
Expected Blood Count Changes
Mycophenolate mofetil causes bone marrow suppression, leading to decreased white blood cell counts rather than elevated counts. The primary hematologic adverse effects include:
- Leukopenia occurs in 23-45% of patients depending on the transplant type and dosing regimen 2
- Anemia affects 26-53% of patients 2
- Thrombocytopenia occurs in 24-42% of patients 2
- Neutropenia can develop, with a mean onset of approximately 4 months after starting therapy 3
Mechanism Behind Leukopenia
The drug works by inhibiting inosine monophosphate dehydrogenase (IMPDH), which blocks the de novo synthesis of guanosine nucleotides that T- and B-lymphocytes critically depend on for proliferation 4. This mechanism inherently suppresses lymphocyte production and causes decreased white blood cell counts, not elevated counts.
Clinical Evidence on White Blood Cell Changes
In a study of 244 SLE patients starting mycophenolate mofetil, there was actually a slight (non-significant) increase in white blood cell count from baseline (6.63 to 7.01), but this was not leukocytosis—it represented normalization in patients who were already leukopenic from their underlying disease. 5 Importantly, patients with baseline WBC <3000/mm³ showed significant improvement (2.57 to 5.13, P=0.0047), but this was correction of severe leukopenia, not development of leukocytosis 5.
Monitoring Requirements for Bone Marrow Suppression
Because leukopenia is a principal adverse effect, intensive CBC monitoring is mandatory:
- Weekly CBC counts for the first 4 weeks 1
- Twice monthly for months 2-3 1
- Monthly for months 4-12 1
- Every 1-3 months indefinitely thereafter 1
This monitoring schedule exists specifically because mycophenolate mofetil causes cytopenias, not elevated blood counts 1.
Clinical Pitfall to Avoid
Do not confuse the drug's immunosuppressive mechanism with infection-related leukocytosis. While mycophenolate mofetil increases the risk of bacterial infections (which can cause reactive leukocytosis), the drug itself causes leukopenia 5. If a patient on mycophenolate develops leukocytosis, investigate for infection or other causes—the elevated white count is not a direct drug effect 1, 2.
When Leukocytosis Occurs in Patients on Mycophenolate
If leukocytosis develops in a patient taking mycophenolate mofetil:
- Evaluate for bacterial infection, as the drug increases infection risk (bacterial infections increased from 4% to 9% in one study, P=0.0036) 5
- Consider opportunistic infections, which occur more frequently with immunosuppression 2
- Assess for underlying disease activity or other medications that might cause leukocytosis 2
- The leukocytosis is NOT caused by the mycophenolate itself 1, 2, 5